MedRhythms, Inc.

High-Level Overview

MedRhythms, Inc. is a neurorehabilitation company developing next-generation digital therapeutics that use a proprietary platform combining sensors, software, music, and neuroscience to improve walking, mobility, and functional outcomes for patients with neurological conditions like stroke, multiple sclerosis, and Parkinson's disease.[1][2] The platform delivers Rhythmic Auditory Stimulation (RAS), an evidence-based intervention, enabling at-home therapy that scales beyond limited clinical settings, serving chronic stroke survivors and others with gait disorders while partnering with top rehabilitation hospitals.[1][2][3] With $5.7M in total funding across three rounds, the company has achieved milestones like FDA listing for its InTandem™ (MR-001) product in 2023 and a collaboration with Universal Music Group for curated music content.[4][6]

Origin Story

Founded in 2015 by Co-Founder and CEO Brian Harris, a board-certified Neurologic Music Therapist and one of only 350 professionals worldwide with advanced training in neuroscience and music applications, MedRhythms began as a Neurologic Music Therapy (NMT) practice at Spaulding Rehabilitation Hospital, growing into the most comprehensive NMT program in the U.S.[1][3] Harris and his clinicians delivered over 30,000 hours of patient care using RAS and music interventions; in 2017, spotting scalability limits amid rising demand for gait disorder treatments and clinician shortages, they pivoted to technology, launching a digital platform for home-based neurotherapeutics.[1] Early traction included partnerships with hospitals like Burke Rehabilitation and HHM JFK Johnson, New Markets Tax Credit funding for Maine growth, and investments from Maine Venture Fund.[2][3][6]

Core Differentiators

• Proprietary Technology Platform: Integrates sensors, software, and patented music curation processes to deliver personalized RAS therapy, analyzing content for therapeutic value before augmenting and individualizing it for neural circuitry targeting in conditions like stroke and Parkinson's.[1]
• Evidence-Based Scalability: Transitions clinic-only RAS (limited by ~350 trained experts globally) to at-home digital therapeutics, with FDA-listed InTandem™ (MR-001) improving ambulation in chronic stroke patients aged 65+.[1][2][4]
• Universal Music Group Partnership: Provides diverse, culturally rich music libraries, enhancing patient engagement by using familiar tracks screened for neuroscience-backed efficacy.[1][6]
• Clinical Expertise and Outcomes Focus: Backed by extensive NMT delivery (30,000+ hours), targeting sensorimotor, speech/language, and cognitive goals across TBI, stroke, and neurodegenerative diseases, with a "People First" culture emphasizing patient impact.[1][3][5]

Role in the Broader Tech Landscape

MedRhythms rides the digital therapeutics wave in neurorehabilitation, leveraging music's unique ability to engage brain regions for movement, language, and attention—unmatched by other stimuli—amid a $28B annual U.S. outpatient rehab market and 2.5M+ annual stroke/TBI cases.[1][3][6] Timing aligns with post-stroke mobility crises (1 in 6 lifetime risk, over half of 65+ survivors affected) and clinician shortages, amplified by telehealth adoption and AI-driven personalization trends.[1][2][3] Market forces like FDA clearances for prescription digital therapeutics and investor interest in brain health (e.g., Maine-focused funds) favor scalable, non-invasive solutions; MedRhythms influences the ecosystem by advancing RAS evidence, partnering with hospitals and music giants, and expanding NMT accessibility beyond clinics.[1][4][6]

Quick Take & Future Outlook

MedRhythms is poised to expand its pipeline across stroke, MS, Parkinson's, and beyond, building on InTandem™'s FDA listing and UMG collaboration to drive adoption in home-based care.[1][4][6] Trends like AI-personalized neurotech, aging populations, and value-based rehab pricing will shape growth, potentially capturing shares of the massive stroke/TBI market through telehealth integrations and further trials.[3] Its influence may evolve from niche NMT leader to mainstream digital neurotherapeutics player, redefining brain health by proving music's scalable power—starting from Harris's hospital roots to global patient impact.[1][5]